Interaction between Transferrin and Tumor Cell Receptor

Author(s):  
I. URUSHIZAKI ◽  
Y. KOHGO ◽  
Y. URUSHIZAKI ◽  
N. NIITSU
Keyword(s):  
Blood ◽  
2012 ◽  
Vol 120 (22) ◽  
pp. 4334-4342 ◽  
Author(s):  
Qi Zhou ◽  
Irene C. Schneider ◽  
Inan Edes ◽  
Annemarie Honegger ◽  
Patricia Bach ◽  
...  

AbstractTransfer of tumor-specific T-cell receptor (TCR) genes into patient T cells is a promising strategy in cancer immunotherapy. We describe here a novel vector (CD8-LV) derived from lentivirus, which delivers genes exclusively and specifically to CD8+ cells. CD8-LV mediated stable in vitro and in vivo reporter gene transfer as well as efficient transfer of genes encoding TCRs recognizing the melanoma antigen tyrosinase. Strikingly, T cells genetically modified with CD8-LV killed melanoma cells reproducibly more efficiently than CD8+ cells transduced with a conventional lentiviral vector. Neither TCR expression levels, nor the rate of activation-induced death of transduced cells differed between both vector types. Instead, CD8-LV transduced cells showed increased granzyme B and perforin levels as well as an up-regulation of CD8 surface expression in a small subpopulation of cells. Thus, a possible mechanism for CD8-LV enhanced tumor cell killing may be based on activation of the effector functions of CD8+ T cells by the vector particle displaying OKT8-derived CD8-scFv and an increase of the surface density of CD8, which functions as coreceptor for tumor-cell recognition. CD8-LV represents a powerful novel vector for TCR gene therapy and other applications in immunotherapy and basic research requiring CD8+ cell-specific gene delivery.


2003 ◽  
Vol 170 (5) ◽  
pp. 2582-2589 ◽  
Author(s):  
Jeffrey J. Roszkowski ◽  
David C. Yu ◽  
Mark P. Rubinstein ◽  
Mark D. McKee ◽  
David J. Cole ◽  
...  

1993 ◽  
Vol 120 (2) ◽  
pp. 513-521 ◽  
Author(s):  
G P Tuszynski ◽  
V L Rothman ◽  
M Papale ◽  
B K Hamilton ◽  
J Eyal

We have previously shown that peptides derived from the thrombospondin sequence, CSVTCG, promoted tumor cell adhesion. To further investigate this observation, the CSVTCG-tumor cell adhesion receptor from A549 human lung adenocarcinoma cells was isolated and characterized. A single protein peak was isolated by CSVTCG affinity chromatography which also analyzed as a single peak by anion exchange chromatography. The purified protein had a pI of 4.7 and analyzed on SDS-gels as a single band of M(r) = 50,000 under nonreducing conditions and as two protein bands of M(r) = 50,000, and 60,000 under reducing conditions. Purified CSVTCG binding protein (CBP) bound either CSVTCG- or TSP-Sepharose but showed little interaction with either VCTGSC- or BSA-Sepharose. CBP was cell surface exposed. CSVTCG derivatized with [125I] Bolton-Hunter reagent was taken up by cells in a dose-dependent manner and the cell association was inhibited with a monospecific polyclonal anti-CBP antibody. Examination of the cell proteins crosslinked to labeled CSVTCG by SDS-gel electrophoresis revealed one band that comigrated with purified CPB. Using an in vitro binding assay, purified CBP bound mannose, galactose, and glucosamine-specific lectins. CBP bound TSP saturably and reversibly. The binding was Ca+2/Mg+2 ion dependent and inhibited with fluid phase TSP and anti-CBP. Little or no binding was observed on BSA, fibronectin, GRGES, and GRGDS. Heparin, but not lactose, inhibited binding. Anti-CBP IgG and anti-CSVTCG peptide IgG inhibited A549 cell spreading and adhesion on TSP but not on fibronectin and laminin. These results indicate that CBP and the CSVTCG peptide domain of TSP can mediate TSP-promoted tumor cell adhesion.


Blood ◽  
2008 ◽  
Vol 111 (1) ◽  
pp. 328-337 ◽  
Author(s):  
Marco Herling ◽  
Kaushali A. Patel ◽  
Michael A. Teitell ◽  
Marina Konopleva ◽  
Farhad Ravandi ◽  
...  

The T-cell leukemia 1 (TCL1) oncoprotein is overexpressed by chromosomal rearrangement in the majority of cases of T-cell prolymphocytic leukemia (T-PLL). In vitro, TCL1 can modulate the activity of the serine-threonine kinase AKT, a downstream effector of T-cell receptor (TCR) signaling. In a series of 86 T-PLL tumors, we show that expression of TCR, and levels of TCL1 and activated AKT are adverse prognostic markers. High-level TCL1 in TCR-expressing T-PLL is associated with higher presenting white blood cell counts, faster tumor cell doubling, and enhanced in vitro growth response to TCR engagement. In primary tumors and TCL1-transfected T-cell lines, TCR engagement leads to rapid recruitment of TCL1 and AKT to transient membrane activation complexes that include TCR-associated tyrosine kinases, including LCK. Pharmacologic inhibition of AKT activation alters the localization, stability, and levels of these transient TCL1-AKT complexes and reduces tumor cell growth. Experimental introduction and knockdown of TCL1 influence the kinetics and strength of TCR-mediated AKT activation. We propose that in T-PLL, TCL1 represents a highly regulated, targetable modulator of TCR-mediated AKT growth signaling.


2011 ◽  
Vol 7 (8) ◽  
pp. e1002240 ◽  
Author(s):  
Ryan S. Noyce ◽  
Daniel G. Bondre ◽  
Michael N. Ha ◽  
Liang-Tzung Lin ◽  
Gary Sisson ◽  
...  

2018 ◽  
Vol XII (4) ◽  
pp. 76-81 ◽  
Author(s):  
S.V. Sazonov ◽  
A.A. Brilliant ◽  
Yu.M. Brilliant

Sign in / Sign up

Export Citation Format

Share Document